Pfizer Returns Bavencio Rights To Merck KGaA, Closing An IO Era
Executive Summary
The arrangement ends a nearly 10-year collaboration between Pfizer and Merk KGaA on the PD-L1 inhibitor that, despite some success, never reached its ultimate goal.
You may also be interested in...
Stock Watch: Hierarchies Of Drugs Against The Same Target
Rarely does the best-selling product emerge when a newer antibody platform is used to improve on a successful earlier-generation product. Better to play to the platform’s strengths.
Merck’s Keytruda And Seagen’s Padcev Become First PD-1/ADC Combo To Win US Approval
The blockbuster PD-1 inhibitor and antibody-drug conjugate will be used to treat a subset of first-line urothelial carcinoma patients considerably widening Padcev’s market, but rates of peripheral neuropathy with the combination have left some analysts concerned.
Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy
Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.